Finance

Lists
N1VO34:BVMF
Novo Nordisk Bdr
R$ २३.९२
०.००%
(०.००) 1D
अक्टोबर १३, १६:५६:०० GMT-३  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VO34...
Open
R$ २४.०१
High
R$ २४.३६
Low
R$ २३.८०
Mkt. cap
१.२९ खरब
Avg. vol.
३४.८२ हजार
Volume
८.४५ हजार
52-wk high
R$ ४२.४३
52-wk low
R$ २२.९०
Shares outstanding
३.३९ अरब
No. of employees
६७ हजार
Open
R$ २४.०१
High
R$ २४.३६
Low
R$ २३.८०
Mkt. cap
१.२९ खरब
Avg. vol.
३४.८२ हजार
Volume
८.४५ हजार
52-wk high
R$ ४२.४३
52-wk low
R$ २२.९०
Shares outstanding
३.३९ अरब
No. of employees
६७ हजार
News stories
From web sources and news partners
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk Bdr
CEOMaziar Mike Doustdar
Employees६६.७ हजार
Founded१९२३
HeadquartersBagsværd, Capital Region of Denmark, डेनमार्क
Sector-
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
DKK ६.१८ / DKK ५.०३
+२२.८७%beat
Revenue / Est. (DKK)
७८.४९ अरब / ७१.४५ अरब
+९.८६%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
७४.९८ अरब
७९.१४ अरब
९६.८२ अरब
७८.४९ अरब
Cost of goods sold
१४.४७ अरब
१४.१७ अरब
१३.६० अरब
१७.१० अरब
Cost of revenue
१४.४७ अरब
१४.१७ अरब
१३.६० अरब
१७.१० अरब
Research and development expenses
११.४९ अरब
१२.६७ अरब
१०.२८ अरब
११.४६ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१५.७६ अरब
१७.१४ अरब
१३.२२ अरब
१६.३१ अरब
Operating expense
२७.२५ अरब
२९.७३ अरब
२३.६१ अरब
२८.०० अरब
Total operating expenses
४१.७२ अरब
४३.९० अरब
३७.२० अरब
४५.१० अरब
Operating income
३३.२५ अरब
३५.२४ अरब
५९.६२ अरब
३३.३९ अरब
Other non operating income
१.५३ अरब
-२४.१० करोड
-
-
EBT including unusual items
२५.५२ अरब
३४.१८ अरब
६२.१७ अरब
२६.८८ अरब
EBT excluding unusual items
३५.०९ अरब
३७.६२ अरब
६२.१७ अरब
३३.२० अरब
Income tax expense
५.५१ अरब
७.२९ अरब
१३.६२ अरब
५.८९ अरब
Effective tax rate
२१.६०%
२१.३४%
२१.९०%
२१.९०%
Other operating expenses
-
-८.१० करोड
१०.६० करोड
२३.४० करोड
Net income
२०.०१ अरब
२६.८९ अरब
४८.५६ अरब
२०.९९ अरब
Net profit margin
२६.६८%
३३.९८%
५०.१५%
२६.७४%
Earnings per share
४.५०
६.०४
६.६३
६.१८
Interest and investment income
३०.७० करोड
४.४१ अरब
-
१.३१ अरब
Interest expense
-
-४.९७ अरब
-
-१.५० अरब
Net interest expenses
३०.७० करोड
-५६.०० करोड
-
-१८.६० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
३६.४९ अरब
३६.६६ अरब
६३.१३ अरब
३६.९९ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google एपहरू